Cidara to present CD101 data at ACCP and IDWeek meetings
The trials for CD101 were created to assess the drug’s potential treatment of serious infections.
“These presentations showcase the breadth and depth of our work to advance CD101, a compound with demonstrated potential to address the urgent unmet need for new and effective antifungal agents," Cidara President and CEO Jeffrey Stein said. “New solutions that address the unmet needs of and increasing resistance to current standard-of-care treatments have become increasingly critical, as demonstrated by the recent United Nations General Assembly declaration that antimicrobial resistance is a major global health issue. We are developing both IV and topical formulations of CD101 to provide truly differentiated and broadly useful antifungal therapies that will have multiple advantages over existing therapies.”
There were five presentations in all for CD101 between the two meetings.